Percutaneous treatment modalities for mitral regurgitation Nassos - - PowerPoint PPT Presentation

▶
percutaneous treatment modalities for mitral regurgitation
SMART_READER_LITE
LIVE PREVIEW

Percutaneous treatment modalities for mitral regurgitation Nassos - - PowerPoint PPT Presentation

Jul 18, 2023 184 likes •763 views

Percutaneous treatment modalities for mitral regurgitation Nassos Manginas MD FACC, FESC Onassis Cardiac Surgery Center Athens, Greece N=5001 4/2001-7/2001 1 year survival 89,52,3% 96,01,4% p=0,02 Lesions leading to MR Echo

slide-1
SLIDE 1

Percutaneous treatment modalities for mitral regurgitation

Nassos Manginas MD

FACC, FESC

Onassis Cardiac Surgery Center Athens, Greece

slide-2
SLIDE 2
slide-3
SLIDE 3
slide-4
SLIDE 4

N=5001 4/2001-7/2001

slide-5
SLIDE 5
slide-6
SLIDE 6
slide-7
SLIDE 7
slide-8
SLIDE 8

1 year survival 89,5±2,3% 96,0±1,4% p=0,02

slide-9
SLIDE 9
slide-10
SLIDE 10

Lesions leading to MR

slide-11
SLIDE 11
slide-12
SLIDE 12

Echo guidance

  • Echo is the gold standard primary imaging

modality for lesion and dysfunction diagnosis

  • Needs to be reviewed by the Interventional

Cardiologist

  • A nomenclature is needed
  • A preprocedural conference is necessary
slide-13
SLIDE 13
slide-14
SLIDE 14
slide-15
SLIDE 15
slide-16
SLIDE 16
slide-17
SLIDE 17
slide-18
SLIDE 18

E-valve. First Case Performed

slide-19
SLIDE 19
slide-20
SLIDE 20
slide-21
SLIDE 21

EVEREST I Trial Inclusion Criteria

slide-22
SLIDE 22

EVEREST II

slide-23
SLIDE 23
slide-24
SLIDE 24
slide-25
SLIDE 25
slide-26
SLIDE 26
slide-27
SLIDE 27
slide-28
SLIDE 28
slide-29
SLIDE 29

E-valve Immediate Results

slide-30
SLIDE 30
slide-31
SLIDE 31
slide-32
SLIDE 32
slide-33
SLIDE 33
slide-34
SLIDE 34

P3 P2 P1

slide-35
SLIDE 35
slide-36
SLIDE 36

MV TV PV AV

P3 P2 P1

slide-37
SLIDE 37
slide-38
SLIDE 38
slide-39
SLIDE 39
slide-40
SLIDE 40
slide-41
SLIDE 41

Superior or inferior location?

slide-42
SLIDE 42
slide-43
SLIDE 43

CS to LCx relation

Not at risk At risk

slide-44
SLIDE 44

EVOLUTION

Procedural success Safety

Death+MI+tamponade

slide-45
SLIDE 45

EVOLUTION 1 year f/up

slide-46
SLIDE 46

EVOLUTION

Percent responders at 6 months and 1 year

slide-47
SLIDE 47

EVOLUTION II

slide-48
SLIDE 48
slide-49
SLIDE 49
slide-50
SLIDE 50
slide-51
SLIDE 51
slide-52
SLIDE 52
slide-53
SLIDE 53
slide-54
SLIDE 54
slide-55
SLIDE 55

Conclusions 1

  • Percutaneous techniques for mitral

insufficiency are feasible and safe

  • Phase I results confirm the effectiveness
  • f both E-valve and coronary sinus

annuloplasty techniques, respecting the effect of learning curves

  • Appropriate case selection is crucial for

each class of devices

slide-56
SLIDE 56

Conclusions 2

  • Significant knowledge should be acquired
  • n the evaluation of MV anatomy and

dysfunction, and the proper use of echo

  • It is very likely that in the future these

techniques will play a significant role in the management of patients with mitral insufficiency